Abstract
Introduction An analysis on the ECLS use for patients with respiratory or cardiac support in COVID-19 based on an international response to EuroELSO survey, aims to generate a more comprehensive understanding of ECLS role during the recent viral pandemic. Methods EuroELSO announced the survey at the 10th annual congress in London, May 2022. The survey covered 26 multiple-choice questions. Results The survey returned 69 questionnaires from 62 centers across 22 European countries and seven centers across five non-European countries. Most of the centers providing ECLS for COVID-19 patients had more than 30 runs for respiratory support since December 2019. In the same period, at least 31 runs in adult COVID-19 patients have been performed in 48 of 69 centers (69.6%). The reported pediatric data from 18 centers is limited to less than the patients per center. Conclusion Majority of the COVID-19 patients received respiratory ECLS support and adult patients dominated. The indications and contraindications are broadly aligned with available guidelines. Most of the centers considered age >65 or biological age as a relative or absolute contraindication for ECLS in COVID-19. ECLS withdrawal criteria in COVID-19 are controversial because the long-term outcomes after ECLS in COVID-19 and the impact of critical illness and the impact of long-COVID are still not known.
Original language | English |
---|---|
Pages (from-to) | 13-23 |
Number of pages | 11 |
Journal | Perfusion |
Volume | 38 |
Issue number | 1_SUPPL |
Early online date | 1 Jan 2023 |
DOIs | |
Publication status | Published - May 2023 |
Keywords
- ECMO
- extracorporeal membrane oxygenation
- ECLS
- extracorporeal life support
- COVID-19
- SARS-CoV-2
- MEMBRANE-OXYGENATION SUPPORT